DCF — ASPIRUS KEWEENAW HOSPITAL
Enterprise Value: $-117.0M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-117.0M
Enterprise Value
$-36.6M
PV of Cash Flows
$-80.4M
PV of Terminal Value
$-129.5M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $60.9M | $-7.5M | -12.0% | $-10.1M | $-9.2M |
| Year 2 | $62.7M | $-7.1M | -11.0% | $-9.8M | $-8.1M |
| Year 3 | $64.6M | $-6.7M | -10.0% | $-9.4M | $-7.1M |
| Year 4 | $66.5M | $-6.6M | -10.0% | $-9.4M | $-6.4M |
| Year 5 | $68.5M | $-6.6M | -10.0% | $-9.5M | $-5.9M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-117.0M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$59.1M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.12850462552810898
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5